SBIR/STTR Research Award

Improved Characterization of 3D In Vitro Cell Culture Assays for the Drug Discovery Process

Award identifier f00aa3238dcff9117e55c3b3d790588cc9c0d8bafb595653bd77679f31b020baAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,526

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Visikol, Inc.
Proposal award date
2018-08-01
Contract end date
2019-07-31
UEI
E92DHV41MJE3
Solicitation number
PA17-302
Topic code
300

Research abstract

Project Summary The general drug discovery process can be described as a large funnel where thousands of compounds are screened for their efficacy and toxicological profile in the pursuit of developing a therapeutic with specific clinical propertiesThis funnel consists of a battery of biochemical and cellular assays for efficacy and toxicity of compoundsOne of the most important screening components of this funnel is the use of inexpensive and high throughput in vitro cell culture models to evaluate likelihood of efficacy or toxicity in vivoAccurate in vivo correlation is crucial for in vitro models since failure to eliminate unsuccessful candidate compounds in early screens results in failure in more expensive animal human trialsUntil recentlythe majority of in vitro drug screening was conducted on monolayer cell culturesD layers of cells are exposed to a compound of interest and evaluated through imagingflow cytometryor spectrophotometric assaysWhile this approach served as the basis for drug discovery for decadesthere are notable shortcomings in the ability of the results of these simple and inexpensive assays to translate in vivoThe complex three dimensional environment in vivo causes differences in response compared to monolayer cell cultures since monolayer models do not possess the diverse array of cellschemistriesand biochemical environments present in tissuesBecause of the well known limitations with traditional monolayer cell modelspharmaceutical companies have begun to rapidly adoptCAGRD in vitroD culture models since they have been shown to mimic the environment of in vivo tissues more accuratelyHoweverparadoxicallythe current techniques that companies are using to characterize theseD in vitro models do not fully utilize theD data that makes these models an improvement over traditionalD in vitro modelsEven the most comprehensive of high content confocal imaging is limited to visualizing only the surface layers of these modelsThe purpose of this project is to develop threeD in vitro cell culture assays that can be offered as a service to pharmaceutical companies for the drug discovery process that characterize the entirety of these modelsThese assays leverage the patented VisikolHISTO Mtissue clearing technique which has been shown to improveD cell culture characterization by allowing for afold increase in the amount of cells that can be detectedThese assays allow pharmaceutical companies to ask and answer complex mechanistic questions about the efficacy of their compounds which will accelerate the drug discovery process and get therapeutics to patients more quickly Project Narrative The purpose of this project is to develop threeD in vitro cell culture assays that can be offered as a service to pharmaceutical companies for the drug discovery processThese assays leverage the patented VisikolHISTO Mtissue clearing technique which has been shown to improveD cell culture characterization by allowing for afold increase in the amount of cells that can be detectedThese assays allow pharmaceutical companies to ask and answer complex mechanistic questions about the efficacy of their compounds which will accelerate the drug discovery process and get therapeutics to patients more quickly

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2016–2021). Reported award amounts total $3,334,045. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.